Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.3.0.814
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Jul. 31, 2015
Jul. 31, 2014
Jul. 31, 2013
Revenues:      
Clinical laboratory services $ 63,414 $ 58,689 $ 55,889
Product revenues 31,690 32,850 32,526
Royalty and license fee income 2,495 4,408 5,292
Total revenues 97,599 95,947 93,707
Operating expenses:      
Cost of clinical laboratory services 39,589 38,948 38,251
Cost of product revenues 15,183 15,320 16,584
Research and development 3,350 3,141 3,889
Selling, general, and administrative 41,069 41,801 43,654
Provision for uncollectible accounts receivable 2,284 3,063 4,496
Legal fee expense 8,788 6,954 5,813
Legal settlements, net (11,458) (3,100)  
Total operating expenses 98,805 106,127 112,687
Operating loss (1,206) (10,180) (18,980)
Other income (expense):      
Interest (245) (208) (54)
Other 95 194 5
Foreign exchange (loss) gain (936) 289 80
Loss before income taxes (2,292) (9,905) (18,949)
Benefit (provision) for income taxes 7 (72) 712
Net loss $ (2,285) $ (9,977) $ (18,237)
Net loss per common share:      
Basic and diluted (in Dollars per share) $ (0.05) $ (0.23) $ (0.46)
Weighted average common shares outstanding:      
Basic and diluted (in Shares) 45,355 42,561 39,607